Moreover, our results make it tempting to speculate whether inhibitors of ERK phosphorylation (MEK inhibitors), which already are in clinical trials, may improve the response rate of rectal carcinomas to RCT. This evidence concerns the gene MAPK1 and rectal carcinoma.